Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01803399
Other study ID # 112166
Secondary ID
Status Withdrawn
Phase Phase 1
First received February 28, 2013
Last updated January 26, 2015
Start date August 2014
Est. completion date December 2014

Study information

Verified date January 2015
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a randomized, partially-blinded, placebo and moxifloxacin-controlled, single dose, 4-period, balanced crossover study. The primary objective of this study is to separately assess the effects of a therapeutic and supratherapeutic dose of GSK1322322 on the cardiac conduction (corrected QT interval [QTc]) compared with placebo in eligible healthy male and female subjects. Avelox (moxifloxacin hydrochloride) will be used as an open-label positive control in order to validate the sensitivity of the study in detecting QTc change. Approximately 56 healthy subjects will participate in the study for approximately 9 weeks i.e. 30 day Screening period, 4-week Treatment period, and a 7-10 day Follow-up period. There will be 4 treatment periods separated by at least 1 week. Subjects will be admitted to the clinical unit on Day -1 of each dosing period. Each subject will receive each of the four treatment sequences (GSK1322322 1200 milligram [mg] intravenous [IV] over 60 minutes x 1 dose, GSK1322322 3000 mg IV over 60 minutes x 1 dose, GSK1322322 Placebo IV over 60 minutes x 1 dose, moxifloxacin 400 mg administered orally x 1 dose) on Day 1 of each Treatment period in a randomized fashion. Twelve-lead electrocardiogram (ECG), continuous Holter monitoring, laboratory tests, vital sign measurements, and serial pharmacokinetic samples will be collected for up to 24 hours following each treatment. If no clinically significant abnormalities are noted, subjects will be discharged from the clinical research unit after the completion of all assessments on Day 2 in each period and return approximately one week later for the next dosing period. Each individual subject will follow the same dosing schedule at every period. A Follow-up visit will be conducted 7-10 days after administration of the last dose of study medication in treatment period 4.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator feels that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures

- Male or female (of non childbearing potential) between 18 and 65 years of age inclusive, at the time of signing the informed consent

- A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] >40 milli international units [mIU]/millilitre [mL] and estradiol <40 picograms [pg]/mL or <147 picomole [pmol]/litre [L] is confirmatory)

- Male subjects with female partners of child-bearing potential must agree to use one of the following contraception methods from the time of the first dose of study medication until the final follow up visit - Condom plus partner use of a highly effective contraceptive; Abstinence, defined as sexual inactivity consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception

- Body weight >=50 kilograms (kg) for men and >=45 kg for women and body mass index (BMI) within the range 18.5-31.0 kg/(square metre) m^2 (inclusive)

- Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5 x Upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%) at screening and check-in (repeat allowed at check-in only)

- Serum Potassium, Calcium and Magnesium lab parameters within normal limits at screening and check-in (repeat allowed at check-in only)

- QTcB <450 milliseconds (msec) at screening and check-in

- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

Exclusion Criteria:

- History/evidence of any arrhythmia (for example, first, second or third degree heart block, atrial fibrillation, supraventricular tachycardia, sinus bradycardia, junctional rhythm) or clinically significant cardiac disease or procedure(mitral valve regurgitation, heart murmur, angina/ischemia, congenital heart abnormalities, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PCTA). Personal or family history of long QT syndrome

- Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of cholecystectomy, inflammatory bowel disease or pancreatitis. Subjects with active peptic ulcer disease or a history of upper gastrointestinal bleeding

- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)

- History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 grams of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits

- A positive pre-study Hepatitis B surface antigen, positive Hepatitis C antibody result, or a positive test for Human Immunodeficiency Virus (HIV) antibody within 3 months of screening

- A positive pre-study drug/alcohol screen

- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)

- Exposure to more than four new chemical entities within 12 months prior to the first dosing day

- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GlaxoSmithKline (GSK) Medical Monitor the medication will not interfere with the study procedures or compromise subject safety due to potential drug interaction

- History of sensitivity to any of the study medications, quinolone antibiotics, (including moxifloxacin), or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation

- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period

- Pregnant females as determined by positive (serum or urine) Human chorionic gonadotropin (hCG) test at screening or prior to dosing

- Lactating females

- Unwillingness or inability to follow the procedures outlined in the protocol

- Subject is mentally or legally incapacitated

- History of sensitivity to heparin or heparin-induced thrombocytopenia

- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening

- Unable to refrain from consumption of red wine, seville oranges, grapefruit or grapefruit juice (and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices) from 7 days prior to the first dose of study medication

- Exclusion criteria for screening Holter and ECG (a single repeat is allowed for eligibility determination): Heart rate <45 and >100 beats per minute (bpm) for males or <50 and >100 bpm for females; PR Interval <120 and >220 msec; QRS duration <70 and >120 msec; QTc interval (Bazett) >=450 msec (Note: The waveforms must enable the QT interval to be clearly defined); Q wave >30 msec

- Evidence of previous myocardial infarction (does not include ST segment changes associated with repolarization)

- Any conduction abnormality (including but not specific to left or right bundle branch block, Atrioventricular (AV) block [2nd degree or higher], Wolf Parkinson White [WPW] syndrome), sinus pauses>3 seconds, non-sustained or sustained ventricular tachycardia (>=3 consecutive ventricular ectopic beats) or any significant arrhythmia which, in the opinion of the principal investigator and GSK medical monitor, will interfere with the safety of the individual subject

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
GSK1322322 1200 mg
GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes
GSK1322322 3000 mg
GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes
Placebo
Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes
Moxifloxacin
Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in QT duration corrected for heart rate by Fridericia's formula (QTcF) for GSK1322322 as compared with time-matched placebo Triplicate 12-lead Holter ECG measurements for each subject at each time point will be averaged Day 1: -1.5, -1.0 and -0.5 hours pre-dose (average as baseline) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, and 24 hours post-dose (Day 2) of each treatment period No
Secondary Change from baseline in QT duration corrected for heart rate by Bazett's formula (QTcB), Individual (linear) QT correction (QTci), QT, and heart rate (HR) To estimate the effect of single dose IV GSK1322322 (1200 mg and 3000 mg) as compared with placebo. Triplicate 12-lead Holter ECG measurements for each subject at each time point will be averaged Day 1: -1.5, -1.0 and -0.5 hours pre-dose (average as baseline) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, and 24 hours post-dose (Day 2) of each treatment period No
Secondary Change from baseline in QTcB, QTci, QT, and HR To estimate the effect of single dose oral moxifloxacin (400 mg) as compared to placebo. Triplicate 12-lead Holter ECG measurements for each subject at each time point will be averaged Day 1: -1.5, -1.0 and -0.5 hours pre-dose (average as baseline) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, and 24 hours post-dose (Day 2) of each treatment period No
Secondary Plasma concentrations and selected pharmacokinetic (PK) parameters of moxifloxacin PK parameters will include: maximum observed plasma concentration (Cmax); time to Cmax (tmax); area under the plasma concentration-time curve (AUC): from time zero (pre-dose) to last time of quantifiable concentration [AUC (0-t)], from time zero (pre-dose) to 24 hours [AUC (0-24)], and from time zero (pre-dose) extrapolated to infinite time [AUC (0-8)]; apparent terminal phase half-life (t1/2); Systemic clearance of parent drug (CL); and volume of distribution at steady state (Vss), as data permit Day 1: 15 minutes pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, and 24 hours post-dose (Day 2) of each treatment period No
Secondary Plasma concentrations and selected PK parameters of GSK1322322/moxifloxacin To characterize the PK/pharmacodynamics (PD) relationship between GSK1322322/moxifloxacin plasma concentrations (and other PK parameters, if appropriate) and QTcF, QTcF changes relative to placebo (ddQTcF) , QTcB, and QTci Day 1: 15 minutes pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, and 24 hours post-dose (Day 2) of each treatment period No
Secondary Safety and tolerability of GSK1322322 as assessed by change from baseline in 12-lead ECGs Single 12-lead ECGs will be obtained Screening, Day 1 (pre-dose (x3) [mean value as baseline] and 0.5, 1, 1.5, 4, 8, 12 hours post-dose) of each treatment period, and Week 9 No
Secondary Safety and tolerability of GSK1322322 as assessed by change from baseline in vital signs Vital sign measurements will include systolic and diastolic blood pressure, temperature and HR Screening, Day 1 (pre-dose (x3) [mean value as baseline] and 0.5, 1, 1.5, 4, 8, 12 hours post-dose) of each treatment period, and Week 9 No
Secondary Safety and tolerability of GSK1322322 as assessed by number of subjects with adverse events Through 9 weeks No
Secondary Safety and tolerability of GSK1322322 as assessed by change from baseline in toxicity grading of clinical laboratory tests Clinical laboratory tests will include clinical Chemistry, hematology and urinalysis assessments Through 9 weeks No
See also
  Status Clinical Trial Phase
Completed NCT04079790 - Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects Phase 1
Completed NCT01934205 - To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944 Phase 1
Not yet recruiting NCT02177721 - Clinical Benefit, Safety and PK of Raxibacumab in Subjects Exposed to Bacillus Anthracis Phase 4
Suspended NCT01132417 - In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance N/A
Completed NCT00539994 - Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus Phase 2
Completed NCT01610388 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects Phase 1
Completed NCT01262885 - A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects Phase 1
Completed NCT00427141 - A Three-Part Study Of GSK580416 In Healthy Subjects Phase 1
Completed NCT04620486 - Effect of BPA on Anchor Antibiotic Continuity in the ED: Randomized Controlled Trial N/A
Recruiting NCT06451172 - Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis Early Phase 1
Not yet recruiting NCT06440304 - Therapeutic Options for CRAB Phase 4
Completed NCT02292498 - Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections N/A
Completed NCT01587768 - WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics N/A
Withdrawn NCT01039610 - A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc. Phase 1
Completed NCT00259909 - Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD) N/A
Completed NCT00828867 - Single Dose Escalation First Time in Human PK Study Phase 1
Completed NCT01431989 - Amoxicillin Bioequivalence Study Brazil - Fast Phase 1
Completed NCT02778672 - Thermal Imaging of the Lung on a Smartphone to Differentiate Bacterial From Non Bacterial Causes of Pneumonia N/A
Completed NCT00896558 - A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects Phase 1
Completed NCT02045797 - Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections Phase 2